For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...

MDS can cause a significant lack of energy that reduces your quality of life. These tips can help you better manage MDS fatigue. Myelodysplastic syndromes (MDS) is a type of cancer that shows up as a ...

Presentation of the COMMANDS trial offered practice-changing results for luspatercept. COMMANDS: Luspatercept Boosts Population With Lower-Risk Myelodysplastic Syndromes Who Are Freed From Blood ...

Selected coverage of myelodysplastic syndromes and myeloproliferative disease at the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...